Skip to main contentAI and Advanced
/
INDOCO · NSEMarket ticker unavailable · configure an authorised index feed
IN
NSE · Equity shares · Biotechnology & Drugs11.60 · 4.79%
Indoco Remedies INDOCO
NSE:INR 254
BSE:INR 236.35
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for INDOCO
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 242.4
Day rangeINR 235 — INR 258
52-week rangeINR 162.19 — INR 332.2
Volume6.44 L
Market cap2,189.1
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,845.32
Net Income (INR Cr)-95.15
EPS-10.49
Research path: Interpret Indoco Remedies's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
INDOCOIndoco Remedies1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 2,593.27 | 2,429.91 | 2,144.73 |
| Cash Equivalents | 25.93 | Not available | Not available |
| Other Liabilities Total | 45.9 | 47.63 | 45.94 |
| Long Term Debt | 516.02 | 533.2 | 351.73 |
| Common Stock Total | 18.46 | 18.45 | 18.44 |
| Other Current Assets Total | 226.92 | 5.36 | 11.9 |
| Total Assets | 2,593.27 | 2,429.91 | 2,144.73 |
| Current Portof LT Debt/Capital Leases | 531.39 | 89 | 47.3 |
| Cash | 7.06 | 11.34 | 14.13 |
| Total Equity | 939.28 | 1,022 | 1,109.9 |
| Long Term Investments | 14.56 | 1.46 | 1.46 |
| Retained Earnings(Accumulated Deficit) | 920.82 | 936.08 | 1,026.26 |
| Total Common Shares Outstanding | 9.23 | 9.22 | 9.22 |
| Tangible Book Valueper Share Common Eq | 79.99 | 89.95 | 100.04 |
| Goodwill Net | 21.52 | 21.52 | 21.52 |
| Total Liabilities | 1,653.99 | 1,407.92 | 1,034.83 |
| Total Debt | 1,089.75 | 987.57 | 667.98 |
| Short Term Investments | 12.85 | 0.76 | 7.97 |
| Cashand Short Term Investments | 45.84 | 12.1 | 22.1 |
| Total Receivables Net | 515.38 | 513.23 | 528.27 |
| Deferred Income Tax | 4.36 | 13.36 | 11.83 |
| Accounts Receivable-Trade Net | 489.17 | 352.41 | 406.2 |
| Property/Plant/Equipment Total-Net | 1,082.19 | 1,125.18 | 891.09 |
| Minority Interest | -7.17 | -3.62 | 0.6 |
| Total Current Liabilities | 1,052.54 | 807.99 | 612.33 |
| Total Inventory | 405.21 | 452.22 | 372.06 |
| Accounts Payable | 308.52 | 208.13 | 153.64 |
| Other Currentliabilities Total | 212.63 | 55.94 | 45.49 |
| Total Long Term Debt | 558.36 | 542.56 | 364.13 |
| Intangibles Net | 179.41 | 170.72 | 166.49 |
| Other Long Term Assets Total | 98.97 | 10.72 | 11.06 |
| Note Receivable-Long Term | 3.27 | 98.97 | 98.44 |
| Total Current Assets | 1,193.35 | 1,001.34 | 954.67 |
| Capital Lease Obligations | 42.34 | 9.36 | 12.41 |
| Accumulated Depreciation Total | Not available | -618.68 | -553.31 |
| Accrued Expenses | Not available | 98.92 | 109.35 |
| Other Equity Total | Not available | 0.91 | 0.23 |
| Prepaid Expenses | Not available | 18.43 | 20.34 |
| Additional Paid-In Capital | Not available | 66.55 | 64.98 |
| Property/Plant/Equipment Total-Gross | Not available | 1,467.74 | 1,341.52 |
| Notes Payable/Short Term Debt | Not available | 356.01 | 256.55 |
Fundamentals
Valuation and ratios
Valuation
Price to Sale Ratio1.19
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk53.33
Analyst consensus
ConsensusSell
Consensus score3.50
Analyst opinions4
Strong Sell count1
Sell count0
Hold count3
Buy count0
Strong Buy count0
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,936.9 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,375 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,979.4 | 1.69 L | 72.73 | — |
| Cipla | INR 1,406.7 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,118.85 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 58.86%
- FII
- 1.27%
- MF
- 17.16%
- Other
- 22.71%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Indoco Remedies to host Q1 FY2026-2027 earnings call on July 28 - scanx.tradeMarket news · 17 Jul 2026, 12:32 pm
Indoco Remedies to host Q1 FY2026-2027 earnings call on July 28 scanx.trade
Price to book forward of Indoco Remedies Limited – NSE:INDOCO - TradingViewMarket news · 30 Jun 2026, 6:43 am
Price to book forward of Indoco Remedies Limited – NSE:INDOCO TradingView
Indoco Remedies in focus after Goa plant receives EU GMP certification - Moneycontrol.comMarket news · 29 Jun 2026, 7:23 am
Indoco Remedies in focus after Goa plant receives EU GMP certification Moneycontrol.com
Indoco Remedies Goa Facility Receives EU GMP Certification From Malta Medicines Authority - scanx.tradeMarket news · 28 Jun 2026, 12:30 pm
Indoco Remedies Goa Facility Receives EU GMP Certification From Malta Medicines Authority scanx.trade
Indoco Remedies Limited Actuals & Estimates (NSE:INDOCO) - TradingViewMarket news · 26 Jun 2026, 4:54 pm
Indoco Remedies Limited Actuals & Estimates (NSE:INDOCO) TradingView
Indoco Remedies Goa Plant successfully clears Malta Medicines Authority audit - Express PharmaMarket news · 26 Jun 2026, 1:34 pm
Indoco Remedies Goa Plant successfully clears Malta Medicines Authority audit Express Pharma
Corporate actions
Events
- board MeetingsQuarterly Results
- dividendRs.0.2000 per share(10%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.0.2000 per share(10%)Final Dividend
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Indoco Remedies
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Indoco Remedies Limited is an India-based fully integrated, research-oriented pharmaceutical company. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company caters to both Domestic and International markets. Its products include SENSODENT-K, HOMIDE, DEXOREN-S, LORCHEK-MR, SENSOFORM, KIDODENT, NINAF, KARVOL PLUS, CYCLOPAM, LIGNOX+ADRENLINE, NOXA, CITAL-UTI, RENOLEN, REXIDIN-M, CITAL, SENSODENT-KF, CARMICIDE, TOBAREN-DM, FEBREX PLUS, SCABEX, CLOBEN-G, MOFLOREN-BF, OTOREX, ZINCOREN, SENOLIN, LIGNOX, HEMSYL, FEDRIS, REXIDIN, VEPAN, OXIPOD, TURBOCORT, MACUCHEK, and DENTOGEL. The Company has around 11 manufacturing facilities, seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs), supported by a research and development center and a clinical research organization facility.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- INDOCO
- BSE Code
- 532612
Questions
Stock FAQ
What is the symbol and ISIN of Indoco Remedies?
Indoco Remedies has the symbol INDOCO and ISIN - INE873D01024.
What is the current price of Indoco Remedies?
Indoco Remedies is currently trading at INR 254.00.
What are the year high and year low of Indoco Remedies?
Indoco Remedies has a year high of INR 332.20 and a year low of INR 162.19.
What is the market capitalization of Indoco Remedies?
Indoco Remedies has a market capitalization of INR 2,189.10 crore.
What is the P/E ratio of Indoco Remedies?
Indoco Remedies has a P/E ratio of NA.
What is the dividend yield of Indoco Remedies?
Indoco Remedies has a dividend yield of NA.
How is the financial performance of Indoco Remedies based on revenue, net income, and EPS?
Indoco Remedies has revenue of INR 1,845.32 crore, net income of INR -95.15 crore, and EPS of NA.
What is the book value of Indoco Remedies?
Indoco Remedies has a book value of NA.
What is the debt-to-equity ratio of Indoco Remedies?
Indoco Remedies has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Indoco Remedies?
Indoco Remedies has a price-to-book ratio of NA and a price-to-sales ratio of 1.19.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.